Relmada Therapeutics, Inc. (RLMD)
3.26
-0.02
(-0.61%)
USD |
NASDAQ |
Oct 07, 16:00
3.26
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Enterprise Value : 132.15M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 132.15M |
| October 05, 2026 | 153.48M |
| October 02, 2026 | 166.28M |
| October 01, 2026 | 172.68M |
| September 30, 2026 | 184.41M |
| September 29, 2026 | 180.15M |
| September 28, 2026 | 186.55M |
| September 25, 2026 | 190.81M |
| September 24, 2026 | 188.68M |
| September 23, 2026 | 185.48M |
| September 22, 2026 | 234.55M |
| September 21, 2026 | 226.02M |
| September 18, 2026 | 221.75M |
| September 17, 2026 | 230.28M |
| September 16, 2026 | 232.42M |
| September 15, 2026 | 255.88M |
| September 14, 2026 | 255.88M |
| September 11, 2026 | 264.42M |
| September 10, 2026 | 216.41M |
| September 09, 2026 | 218.55M |
| September 08, 2026 | 235.62M |
| September 04, 2026 | 254.82M |
| September 03, 2026 | 248.42M |
| September 02, 2026 | 266.55M |
| September 01, 2026 | 258.02M |
| Date | Value |
|---|---|
| August 31, 2026 | 247.35M |
| August 28, 2026 | 244.15M |
| August 27, 2026 | 264.42M |
| August 26, 2026 | 267.62M |
| August 25, 2026 | 271.88M |
| August 24, 2026 | 270.82M |
| August 21, 2026 | 276.15M |
| August 20, 2026 | 277.22M |
| August 19, 2026 | 297.48M |
| August 18, 2026 | 299.62M |
| August 17, 2026 | 291.08M |
| August 14, 2026 | 294.28M |
| August 13, 2026 | 288.95M |
| August 12, 2026 | 285.75M |
| August 11, 2026 | 259.08M |
| August 10, 2026 | 266.55M |
| August 07, 2026 | 309.22M |
| August 06, 2026 | 355.09M |
| August 05, 2026 | 362.55M |
| August 04, 2026 | 365.75M |
| August 03, 2026 | 347.62M |
| July 31, 2026 | 348.69M |
| July 30, 2026 | 352.95M |
| July 29, 2026 | 330.55M |
| July 28, 2026 | 340.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.878B |
| Corcept Therapeutics, Inc. | 12.61B |
| Veru, Inc. | 19.01M |
| Johnson & Johnson | 641.85B |
| Eli Lilly & Co. | 1.136T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.91M |
| Total Expenses (Quarterly) | 12.91M |
| EPS Diluted (Quarterly) | -0.1149 |
| Earnings Yield | -28.53% |
| Normalized Earnings Yield | -28.47 |